Art

J-GLOBAL ID：201802241218502366   Reference number：18A0974169

BK-UM in patients with recurrent ovarian cancer or peritoneal cancer: a first-in-human phase-I study

再発卵巣癌または腹膜癌患者におけるBK-UM ヒト第一相試験【JST・京大機械翻訳】

Author (40)： Miyamoto Shingo (Department of Obstetrics and Gynecology, Faculty of Medicine, Fukuoka University, Fukuoka, Japan) ,  Miyamoto Shingo (Center for Advanced Molecular Medicine, Fukuoka, Japan) ,  Yotsumoto Fusanori (Department of Obstetrics and Gynecology, Faculty of Medicine, Fukuoka University, Fukuoka, Japan) ,  Yotsumoto Fusanori (Center for Advanced Molecular Medicine, Fukuoka, Japan) ,  Ueda Taeko (Department of Obstetrics and Gynecology, University of Occupational and Environmental Health School of Medicine, Kitakyushu, Japan) ,  Fukami Tatsuya (Department of Obstetrics and Gynecology, Faculty of Medicine, Fukuoka University, Fukuoka, Japan) ,  Sanui Ayako (Department of Obstetrics and Gynecology, Faculty of Medicine, Fukuoka University, Fukuoka, Japan) ,  Miyata Kohei (Department of Obstetrics and Gynecology, Faculty of Medicine, Fukuoka University, Fukuoka, Japan) ,  Miyata Kohei (Center for Advanced Molecular Medicine, Fukuoka, Japan) ,  Nam Sung Ouk (Department of Obstetrics and Gynecology, Faculty of Medicine, Fukuoka University, Fukuoka, Japan) ,  Fukagawa Satoshi (Department of Obstetrics and Gynecology, Faculty of Medicine, Fukuoka University, Fukuoka, Japan) ,  Fukagawa Satoshi (Center for Advanced Molecular Medicine, Fukuoka, Japan) ,  Katsuta Takahiro (Department of Obstetrics and Gynecology, Faculty of Medicine, Fukuoka University, Fukuoka, Japan) ,  Maehara Miyako (Department of Obstetrics and Gynecology, Faculty of Medicine, Fukuoka University, Fukuoka, Japan) ,  Kondo Haruhiko (Department of Obstetrics and Gynecology, Faculty of Medicine, Fukuoka University, Fukuoka, Japan) ,  Miyahara Daisuke (Department of Obstetrics and Gynecology, Faculty of Medicine, Fukuoka University, Fukuoka, Japan) ,  Shirota Kyoko (Department of Obstetrics and Gynecology, Faculty of Medicine, Fukuoka University, Fukuoka, Japan) ,  Yoshizato Toshiyuki (Department of Obstetrics and Gynecology, School of Medicine, Kurume University, Kurume, Japan) ,  Kuroki Masahide (Center for Advanced Molecular Medicine, Fukuoka, Japan) ,  Kuroki Masahide (Department of Biochemistry, Faculty of Medicine, Fukuoka University, Fukuoka, Japan) ,  Nishikawa Hiroaki (Department of Cardiology, Faculty of Medicine, Fukuoka University, Fukuoka, Japan) ,  Saku Keijiro (Department of Cardiology, Faculty of Medicine, Fukuoka University, Fukuoka, Japan) ,  Tsuboi Yoshio (Department of Neurology, Faculty of Medicine, Fukuoka University, Fukuoka, Japan) ,  Ishitsuka Kenji (Department of Hematology and Immunology, Kagoshima University Medical and Dental Hospital, Kagoshima, Japan) ,  Takamatsu Yasushi (Department of Internal Medicine, Division of Medical Oncology, Hematology and Infectious Disease, Faculty of Medicine, Fukuoka University, Fukuoka, Japan) ,  Tamura Kazuo (Department of Internal Medicine, Division of Medical Oncology, Hematology and Infectious Disease, Faculty of Medicine, Fukuoka University, Fukuoka, Japan) ,  Matsunaga Akira (Department of Laboratory Medicine, Faculty of Medicine, Fukuoka University, Fukuoka, Japan) ,  Hachisuga Toru (Department of Obstetrics and Gynecology, University of Occupational and Environmental Health School of Medicine, Kitakyushu, Japan) ,  Nishino Shinsuke (Kanonji Institute, Research Foundation for Microbial Diseases of Osaka University, Kanonji, Japan) ,  Odawara Takashi (Kanonji Institute, Research Foundation for Microbial Diseases of Osaka University, Kanonji, Japan) ,  Maeda Kazuhiro (Kanonji Institute, Research Foundation for Microbial Diseases of Osaka University, Kanonji, Japan) ,  Manabe Sadao (Kanonji Institute, Research Foundation for Microbial Diseases of Osaka University, Kanonji, Japan) ,  Ishikawa Toyokazu (Kanonji Institute, Research Foundation for Microbial Diseases of Osaka University, Kanonji, Japan) ,  Okuno Yoshinobu (Kanonji Institute, Research Foundation for Microbial Diseases of Osaka University, Kanonji, Japan) ,  Ohishi Minako (Department of Cell Biology, Research Institute for Microbial Disease, Osaka University, Suita, Japan) ,  Hikita Tomoya (Department of Cell Biology, Research Institute for Microbial Disease, Osaka University, Suita, Japan) ,  Hikita Tomoya (Department of Biochemistry, School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka, Japan) ,  Mizushima Hiroto (Department of Cell Biology, Research Institute for Microbial Disease, Osaka University, Suita, Japan) ,  Iwamoto Ryo (Department of Cell Biology, Research Institute for Microbial Disease, Osaka University, Suita, Japan) ,  Mekada Eisuke (Department of Cell Biology, Research Institute for Microbial Disease, Osaka University, Suita, Japan)
Material： BMC Cancer (Web)
Volume： 17  Issue： 1  Page： 89  Publication year： 2017 
JST Material Number： U7305A  ISSN： 1471-2407  Document type： Article
Article type： 原著論文  Country of issue： United Kingdom (GBR)  Language： ENGLISH (EN)

Abstract/Point： Background BK-UM (CRM197) is a...

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=18A0974169&from=J-GLOBAL&jstjournalNo=U7305A") }}

Thesaurus term： Safety ,  pharmacokinetics ,  EGF ,  *phase 1 study ,  *ovarian tumor ,  *Recurrence ,  *patient ,  repeated administration ,  Serum ,  Diphtheria Toxin ,  *human ,  tolerability ,  HB-EGF ,  recommended dosage ,  adverse reaction
Semi thesaurus term： 有害事象 , 【Automatic Indexing@JST】

Author keywords (5)： BK-UM ,  HB-EGF ,  Ovarian cancer ,  Phase-I study ,  Targeted therapy

JST classification (2)： Clinical application of antitumor(=antineoplastic)drugs  (GW16020L) ,  Drug therapy(=pharmacotherapy)for tumors  (GE03032C)

Reference (26)：

• Lancet Oncol; Mechanisms of transcoelomic metastasis in ovarian cancer; DS Tan, R Agarwal, SB Kaye; 7; 2006; 925-34; 10.1016/S1470-2045(06)70939-1; CR1;
• J Clin Oncol; Does aggressive surgery only benefit patients with less advanced ovarian cancer? Results from an international comparison within the SCOTROC-1 Trial; SC Crawford, PA Vasey, J Paul, A Hay, JA Davis, SB Kaye; 23; 2005; 8802-11; 10.1200/JCO.2005.02.1287; CR2;
• Expert Opin Pharmacother; Treatment of platinum-resistant ovarian cancer; EL Trimble, J Wright, MC Christan; 2; 2001; 1299-306; 10.1517/14656566.2.8.1299; CR3;
• Lancet Oncol; Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial; AM Oza, AD Cook, J Pfisterer, A Embleton, JA Ledermann, E Pujade-Lauraine; 16; 2015; 928-36; 10.1016/S1470-2045(15)00086-8; CR4;
• Lancet; Ovarian cancer; GC Jayson, EC Kohn, HC Kitchener, JA Ledermann; 384; 2014; 1376-88; 10.1016/S0140-6736(13)62146-7; CR5;

Terms in the title (6)： 再発卵巣癌 ,  腹膜 ,  癌患者 ,  Bk ,  ヒト ,  第一相試験